DPP-4 traffic jam
By Michael Flanagan Senior Writer
Unlike the next wave of GLP-1 mimetics, which are expected to offer successively less frequent dosing and easier compliance for Type II diabetics, data on the new contingent of DPP-4 inhibitors at last week's American Diabetes Association meeting didn't show any obvious advantages over Januvia sitagliptin from Merck & Co. Inc.
Given the apparent similarities in potency, dosing and side effect profiles, the question remains whether doctors will use a newer DPP-4 instead of one with a proven track record. The first company to test the waters could be Takeda Pharmaceutical Co. Ltd., which submitted an NDA late last year for